HGF and head and neck squamous cell carcinoma: Indeed, recent data from the literature of a phase 2 trial [23] investigated the efficacy of ficlatuzumab (monoclonal anti-HGF antibody) in combination with cetuximab in patients with pan-refractory R/M HNSCC.